46 related articles for article (PubMed ID: 29709973)
1. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.
Wohl DA; Waters D; Simpson RJ; Richard S; Schnell A; Napravnik S; Keys J; Eron JJ; Hsue P
Clin Infect Dis; 2008 Oct; 47(8):1105-8. PubMed ID: 18781882
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and management of dyslipidemia in patients with HIV infection.
Green ML
J Gen Intern Med; 2002 Oct; 17(10):797-810. PubMed ID: 12390557
[TBL] [Abstract][Full Text] [Related]
3. Association between lipid-lowering agents and severe hyponatremia: a population-based case-control study.
Skov J; Falhammar H; Calissendorff J; Lindh JD; Mannheimer B
Eur J Clin Pharmacol; 2021 May; 77(5):747-755. PubMed ID: 33215235
[TBL] [Abstract][Full Text] [Related]
4. New options in the treatment of lipid disorders in HIV-infected patients.
da Silva EF; Bárbaro G
Open AIDS J; 2009 Jul; 3():31-7. PubMed ID: 19639034
[TBL] [Abstract][Full Text] [Related]
5. Dyslipidemia and cardiovascular disease risk profiles of patients attending an HIV treatment clinic in Harare, Zimbabwe.
Zhou DT; Kodogo V; Chokuona KF; Gomo E; Oektedalen O; Stray-Pedersen B
HIV AIDS (Auckl); 2015; 7():145-55. PubMed ID: 25999764
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Switching Between Antiretroviral Agents Versus Introducing Lipid-Lowering Agents for HAART-Induced Dyslipidemia.
Mafumhe TF; Regalado G; Olojede SO; Lawal SK; Azu OO
Clin Ther; 2024 Jun; ():. PubMed ID: 38851959
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the Therapeutic Lifestyle Change Diet Intervention to Improve Biochemical Markers of Cardiovascular Diseases in HIV-Infected Patients with Dyslipidemia.
Singhato A; Booranasuksakul U; Khongkhon S; Rueangsri N
Ann Nutr Metab; 2024 Apr; ():1-9. PubMed ID: 38631311
[TBL] [Abstract][Full Text] [Related]
8. IMPROVE-IT: A Final Closure to Carcinogenicity of Ezetimibe?
Lewis EF; Rhee JW
JACC CardioOncol; 2020 Sep; 2(3):397-399. PubMed ID: 34396247
[TBL] [Abstract][Full Text] [Related]
9. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
10. Short-Term Efficacy and Safety of Adding Ezetimibe to Current Regimen of Lipid-Lowering Drugs in Human Immunodeficiency Virus-Infected Thai Patients Treated with Protease Inhibitors.
Boonthos K; Puttilerpong C; Pengsuparp T; Manosuthi W
Jpn J Infect Dis; 2018 May; 71(3):220-224. PubMed ID: 29709973
[TBL] [Abstract][Full Text] [Related]
11. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.
Hiransuthikul N; Hiransuthikul P; Kanasook Y
Southeast Asian J Trop Med Public Health; 2007 Jan; 38(1):69-77. PubMed ID: 17539249
[TBL] [Abstract][Full Text] [Related]
12. Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.
Saeedi R; Johns K; Frohlich J; Bennett MT; Bondy G
Lipids Health Dis; 2015 Jun; 14():57. PubMed ID: 26087958
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
Negredo E; Moltó J; Puig J; Cinquegrana D; Bonjoch A; Pérez-Alvarez N; López-Blázquez R; Blanco A; Clotet B; Rey-Joly C
AIDS; 2006 Nov; 20(17):2159-64. PubMed ID: 17086055
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
